Pediatric genitourinary tumors

Current Opinion in Oncology

Volumn 19, Issue 3, 2007, Pages 248-253

  Castellino, Sharon M ^a   McLean, Thomas W ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Childhood cancer; Genitourinary; Rhabdomyosarcoma; Wilms' tumor

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; CPG OLIGODEOXYNUCLEOTIDE; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; INTERLEUKIN 2; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIRAPAZAMINE; VASCULOTROPIN ANTIBODY; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOMYOPATHY; CHILD; CHILDHOOD CANCER; CLEAR CELL SARCOMA; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; GENE EXPRESSION; GENE MUTATION; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; MESOBLASTIC NEPHROMA; MINIMALLY INVASIVE SURGERY; MOLECULAR GENETICS; NEPHROBLASTOMA; PARTIAL NEPHRECTOMY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RHABDOID TUMOR; RHABDOMYOSARCOMA; TESTIS TUMOR; UROGENITAL TRACT TUMOR;

CHILD; FEMALE; HUMANS; KIDNEY NEOPLASMS; LOSS OF HETEROZYGOSITY; MALE; NEOPLASM STAGING; PROGNOSIS; RHABDOMYOSARCOMA; UROGENITAL NEOPLASMS; WILMS TUMOR;

EID: 34247161829     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3280ad43ce     Document Type: Review

References (29)

1. Metzger ML, Dome JS. Current therapy for Wilms' tumor. Oncologist 2005; 10:815-826.
2. Perlman EJ. Pediatric renal tumors: practical updates for the pathologist. Pediatr Dev Pathol 2005; 8:320-338.
3. Hall G, Grant R, Weitzman S, et al. Predictors of surgical outcome in Wilms' tumor: a single-institution comparative experience. J Pediatr Surg 2006; 41:966-971. A single institution comparison of primary chemotherapy versus primary nephrectomy for Wilms' tumor indicates comparable tumor spill rates, and that tumor spill did not negatively impact OS.
4. Spreafico F, Bellani FF. Wilms' tumor: past, present and (possibly) future. Expert Rev Anticancer Ther 2006; 6:249-258. An excellent review of Wilms' tumor, highlighted by comparing experiences in North America, the UK and Italy.
5. Mitchell C, Pritchard-Jones K, Shannon R, et al. Immediate nephrectomy versus preoperative chemotherapy in the management of nonmetastatic Wilms' tumour: results of a randomised trial (UKW3) by the UK Children's Cancer Study Group. Eur J Cancer 2006; 42:2554-2562. A randomized trial indicating that delayed surgery with preoperative chemotherapy improves tumor stage distribution of Wilms' tumor, but does not alter event-free survival or OS.
6. Duarte RJ, Denes FT, Cristofani LM, et al. Further experience with laparoscopic nephrectomy for Wilms' tumour after chemotherapy. BJU Int 2006; 98:155-159.
7. Hamilton TE, Green DM, Perlman EJ, et al. Bilateral Wilms' tumor with anaplasia: lessons from the National Wilms' Tumor Study. J Pediatr Surg 2006; 41:1641-1644.
8. Dome JS, Cotton CA, Perlman EJ, et al. Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study. J Clin Oncol 2006; 24:2352-2358. ANWTS report by leaders in the field, on clinical features and outcomes of anaplastic histology, and the benefit of VP16 and cyclophosphamide in this group of patients.
9. Lall A, Pritchard-Jones K, Walker J, et al. Wilms' tumor with intracaval thrombus in the UK Children's Cancer Study Group UKW3 trial. J Pediatr Surg 2006; 41:382-387.
10. Ribeiro RC, Schettini ST, Abib Sde C, et al. Cavectomy for the treatment of Wilms tumor with vascular extension. J Urol 2006; 176:279-283; discussion 283-284.
11. Whyte SD, Mark Ansermino J. Anesthetic considerations in the management of Wilms' tumor. Paediatr Anaesth 2006; 16:504-513. Nice review of perioperative considerations, including the recognition and attention to intracaval thrombus.
12. Shamberger RC, Haase GM, Argani P, et al. Bilateral Wilms' tumors with progressive or nonresponsive disease. J Pediatr Surg 2006; 41:652-657; discussion 652-657. Excellent study regarding the challenges of bilateral Wilms' tumor, and specifically the contributors to nonresponsive disease.
13. Maas MH, Cransberg K, van Grotel M, et al. Renin-induced hypertension in Wilms tumor patients. Pediatr Blood Cancer 2006; 22 June [Epub ahead of print].
14. Breslow NE, Beckwith JB, Haase GM, et al. Radiation therapy for favorable histology Wilms tumor: prevention of flank recurrence did not improve survival on National Wilms Tumor Studies 3 and 4. Int J Radiat Oncol Biol Phys 2006; 65:203-209.
15. Ehrlich PF, Hamilton TE, Grundy P, et al. The value of surgery in directing therapy for patients with Wilms' tumor with pulmonary disease: a report from the National Wilms' Tumor Study Group (National Wilms' Tumor Study 5). J Pediatr Surg 2006; 41:162-167; discussion 162-7.
16. Green DM, Cotton CA, Malogolowkin M, et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D: a report from the National Wilms Tumor Study Group. Pediatr Blood Cancer 2006; 17 March [Epub ahead of print].
17. Grundy PE, Breslow NE, Li S, et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol 2005; 23:7312-7321.
18. Dome JS, Bockhold CA, Li SM, et al. High telomerase RNA expression level is an adverse prognostic factor for favorable-histology Wilms' tumor. J Clin Oncol 2005; 23:9138-9145.
19. Scott RH, Stiller CA, Walker L, Rahman N. Syndromes and constitutional chromosomal abnormalities associated with Wilms tumour. J Med Genet 2006; 43:705-715. This is a thorough review of syndromes and other chromosomal disorders which have an increased risk of developing Wilms' tumor; it also quantifies this risk as accurately as possible.
20. Rong Y, Cheng L, Ning H, et al. Wilms' tumor 1 and signal transducers and activators of transcription 3 synergistically promote cell proliferation: a possible mechanism in sporadic Wilms' tumor. Cancer Res 2006; 66:8049-8057.
21. Timofeeva OA, Plisov S, Evseev AA, et al. Serine-phosphorylated STAT1 is a prosurvival factor in Wilms' tumor pathogenesis. Oncogene 2006; 25:7555-7564.
22. Spraggon L, Dudnakova T, Slight J, et al. hnRNP-U directly interacts with WT1 and modulates WT1 transcriptional activation. Oncogene 2006; 21 August [Epub ahead of print].
23. Singh KP, Roy D. SKCG-1: a new candidate growth regulatory gene at chromosome 11q23.2 in human sporadic Wilms tumours. Br J Cancer 2006; 94:1524-1532.
24. Yuan E, Li CM, Yamashiro DJ, et al. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors. Mol Cancer Res 2005; 3:493-502.
25. Ruteshouser EC, Hendrickson BW, Colella S, et al. Genome-wide loss of heterozygosity analysis of WT1-wild-type and WT1-mutant Wilms tumors. Genes Chromosomes Cancer 2005; 43:172-180.
26. Natrajan R, Williams RD, Hing SN, et al. Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse. J Pathol 2006; 210:49-58. This study characterized 76 favorable histology Wilms' tumors using microarray-based comparative genomic hybridization and RT-PCR, and identified many candidate genes that may play a role in tumors that recur after therapy.
27. Yang Y, Niu ZB, Hou Y, Wang CL. The expression of HSP70 and HSP90alpha in children with Wilms tumor. J Pediatr Surg 2006; 41:1062-1066.
28. Li W, Kessler P, Williams BR. Transcript profiling of Wilms tumors reveals connections to kidney morphogenesis and expression patterns associated with anaplasia. Oncogene 2005; 24:457-468.
29. Zirn B, Samans B, Spangenberg C, et al. All-trans retinoic acid treatment of Wilms tumor cells reverses expression of genes associated with high risk and relapse in vivo. Oncogene 2005; 24:5246-5251.